Beam Therapeutics presented new clinical data from its Phase 1/2 trial of BEAM-302, a gene editing therapy targeting Alpha-1 Antitrypsin Deficiency (AATD), showing safety, durable efficacy, and reduction in disease markers. The therapy aims to correct the root genetic cause of AATD with a single dose, potentially treating both lung and liver disease manifestations. Beam plans to expand the trial with 50 more patients and pursue accelerated FDA approval, aiming for a pivotal study start in late 2026. This approach represents a significant advancement in treating AATD and gene editing medicine overall.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
Fundstrat's Granny Shot US-Small & Mid-Cap ETF (GRNJ) has delivered strong year-to-date returns, beating similar ETFs like VOT and VOO despite its higher 0.75% expense ratio. The fund targets stocks at the intersection of major secular trends, partic...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
